D. Gómez, P. Peremiquel-Trillas, X. Matias-Guiu, X. Bosch, L. Bruni, L. Alemany, L. Costas, M. Diaz, J. M. Martínez, S. Fernández, J. Frias-Gomez, S. Paytubi, S. de Sanjosé, M. Pineda, J. Brunet, J. Ponce
New approaches are being developed to early detect endometrial cancer (EC) using molecular testing. Mathematical models are commonly used in these situations with the aim of predicting future benefits and costs of novel interventions.
A Markov model was developed to simulate a cohort of women with postmenopausal bleeding (PMB) to assess a new molecular testing strategy in relation to the current practice. For each strategy, the model predicts the life expectancy, QALYs, number of hysterectomies, EC prevalence, incidence, mortality and lifetime costs. The strategies were compared using the incremental cost-effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were conducted to determine the robustness of the results.
The model shows that the introduction of molecular testing to diagnose EC in PMB women has the potential to be cost-effective. This study provides decision-makers with useful information to guide decisions about health resource allocation.
Palabras clave: markov model, sensitivity analysis, cost-effectiveness analysis, cancer, diagnostic strategies
Programado
Aplicaciones de la Estadística I
10 de junio de 2022 10:10
A15
